Original Article

Cancer Chemotherapy and Pharmacology

, Volume 73, Issue 1, pp 191-198

Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer

  • Seung Woo YiAffiliated withDepartment of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine
  • , Dae Ryong KangAffiliated withBiostatistics Collaboration Unit, Yonsei University College of Medicine
  • , Kyung Sik KimAffiliated withDepartment of Surgery, Yonsei University College of Medicine
  • , Mi Suk ParkAffiliated withDepartment of Diagnostic Radiology, Yonsei University College of Medicine
  • , Jinsil SeongAffiliated withDepartment of Radiation Oncology, Yonsei University College of Medicine
  • , Jeong Youp ParkAffiliated withDepartment of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine
  • , Seung Min BangAffiliated withDepartment of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine
  • , Si Young SongAffiliated withDepartment of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine
  • , Jae Bock ChungAffiliated withDepartment of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine
    • , Seung Woo ParkAffiliated withDepartment of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Purpose

There is no established standard treatment for patients with locally advanced biliary tract cancer (BTC).

Methods

We analyzed the treatment results of locally advanced BTC from Jan 1995 to Dec 2010 at single institution of South Korea with retrospective study. One hundred and seventy-six patients were eligible to investigate the treatment response and toxicity. We treated these patients with 5-fluorouracil (5-FU)- or gemcitabine (GEM)-based concurrent chemoradiotherapy (CCRT) or best supportive care (BSC). The primary end point was overall survival.

Results

Of these locally advanced BTC patients, 106 patients received CCRT and 70 patients were treated with BSC. The median overall survival was 42.57 weeks (95 % confidence interval [CI], 35.85–49.30) in CCRT group and 13.29 weeks (95 % CI 10.42–16.15) in BSC group (P < 0.001). Nausea and anemia were the most common toxicities observed.

Conclusions

Patients with locally advanced BTC who were treated with 5-FU-based or GEM-based CCRT seem to have a better survival than those who received BSC. The treatment-related toxicity was mild. GEM-based or 5-FU-based CCRT showed similar survival advantages.

Keywords

Biliary tract cancer Concurrent chemoradiation GB cancer Locally advanced